Kornimate/medical-research-clean huggingface dataset:
the use of exosomes in craniofacial neuralgia

Conditions: Neuralgia

Summary: this study is designed to evaluate the safety and efficacy of exosome deployment in patients with craniofacial neuralgia. secondarily, this study is designed to rigorously evaluate for any adverse events that may be related to the administration and reception of exosomes.

the present study is designed to amplify the delivery of growth factors and anti-inflammatory agents to localized targets (determined by specific condition) by using focused transcranial ultrasound prior to intravenous infusion of exosomes. exosomes delivered intravenously can be demonstrated to cross the blood brain barrier naturally. exosomes are thought to play a normal physiological role in intercellular signaling, and demonstrate anti-inflammatory and pro-growth effects in preclinical models and clinical cases reports. clinical trials have deployed exosomes intravenously and with intracerebral and intrathecal injection, and have claimed safety and clinical efficacy. focused ultrasound has been shown to enhance local blood flow and has been presented as a non-invasive means of targeting delivery of therapeutic agents.

Eligibility criteria:
inclusion criteria: * male or female at least 18 years of age * clinical diagnosis of craniofacial neuralgia exclusion criteria: * subjects unable to give informed consent * subjects who would not be able to lay down without excessive movement in a calm environment sufficiently long enough to be able to achieve sleep * recent surgery or dental work within 3 months of the scheduled procedure. * pregnancy, women who may become pregnant or are breastfeeding * advanced terminal illness * any active cancer or chemotherapy * bone marrow disorder * myeloproliferative disorder * sickle cell disease * primary pulmonary hypertension * immunocompromising conditions and/or immunosuppressive therapies * macular degeneration * subjects with scalp rash or open wounds on the scalp (for example from treatment of squamous cell cancer) * advanced kidney, pulmonary, cardiac or liver failure * subjects with vascular causes of dementia * bleeding disorder, untreated
metabolic phenotyping and follow-up of patients with and without diabetes after new onset of stemi

Conditions: ST-segment Elevation Myocardial Infarction (STEMI); Diabetes Mellitus; Insulin Resistance; Non-Alcoholic Fatty Liver Disease

Summary: the aim of the prospective observational distemi-study in people with and without diabetes mellitus (di) after new onset of st-segment elevation myocardial infarction (stemi) aged 18-80 years at inclusion into the study is to characterize in detail the clinical, metabolical, immunological and vascular phenotype, investigate the interplay between myocardial remodelling and the metabolic phenotype, monitor the progression of the disease and compare the phenotype of stemi people with diabetes mellitus to people with prediabetes and glucose tolerant people.

in detail, the following questions will be answered: 1. do distinct metabolic phenotypes (with respect to insulin secretion, insulin sensitivity, circulating free fatty acids and ectopic lipid storage, especially in the liver) determine myocardial infarct size and decline of contractile function of the remote myocardium? 2. which factors modify the progression of the disease (insulin resistance, ectopic lipid storage, subclinical inflammation, abnormal energy metabolism)? people are thoroughly examined at baseline and one year after stemi. 3. can we identify risk profiles and their relevance for development of diabetes-associated complications as well as long-term progression of diabetes? 4. can we improve risk assessment algorithms for targeted therapy in line with precision medicine?

Eligibility criteria:
inclusion criteria: * condition after new onset of st-segment elevation myocardial infarction (stemi) * age 18-80 years * hba1c \<9.0% * people with diagnosis of diabetes mellitus according to ada and ddg criteria (i.e. hba1c ≥6.5% and/or pathological oral glucose tolerance test) * healthy people with normal glucose tolerance status according to ada and ddg criteria (i.e. hba1c \<5.7% and normal ogtt) * people with impaired glucose metabolism ("prediabetes") according to ada and ddg criteria (i.e. impaired fasting glucose and/or impaired glucose tolerance and/or hba1c 5.7-6.4%) * consent-able, hemodynamically stable people, without sedation (e.g. opiates) or other interfering medication (e.g. catecholamines) exclusion criteria: * diabetes mellitus category 3 a-h (ada criteria), gestational diabetes * current pregnancy * infectious diseases, acute infections / fever * immunosuppressive therapy * severe chronic renal, liver or heart disease (e.g. serum creatinin ≥1.6 mg/dl, peripheral artery occlusive disease stage iv) * malignant diseases * severe chronic psychiatric illness or addiction * participation in an intervention trial

Keywords: st-segment elevation myocardial infarction stemi cardiovascular diseases cvd diabetes mellitus normal glucose tolerance non-alcoholic fatty liver disease nafld liver fibrosis
efficacy of an u-shape automatic electric toothbrush in plaque removal

Conditions: Dental Plaque; Toothbrushing

Summary: over time, many different types of manual and electric toothbrushes have been produced. a systematic review has shown that some electric toothbrushes are more effective at removing bacterial plaque than manual toothbrushes. a new u-shaped electric toothbrush with silicone bristles has recently been produced that has a fully automatic and simultaneous action on both arches. however, its efficacy in removing bacterial plaque is not clear at the moment, as no randomized study has been published on this type of toothbrush. the aim of this study is to compare the efficacy in terms of bacterial plaque removal in a single use of a new automatic u-shaped electric toothbrush, compared with the usual home toothbrushing procedure, a conventional electric toothbrush, and negative control (no toothbrushing) in a group of volunteer students of the school of dentistry of the university of florence, italy. primary endpoint will be the difference in "full mouth plaque score" between before and after brushing. secondary endpoints will be feeling of "clean mouth" evaluated on a vas (visual analogue scale) scale from 0 to 10 where 0 indicates no feeling of clean mouth and 10 maximum feeling of clean mouth. this study will be a monocentric, randomized, controlled, superiority, cross-over study, with blind examiner and 4 therapies (u-shaped electric toothbrush, usual home toothbrushing procedure, conventional electric toothbrush, no toothbrushing), carried out in a single session with an interval of one week between the 4 therapies. study population will be students of the school of dentistry who are healthy volunteers. number of patients to be enrolled: 22. inclusion criteria: age between 18 and 30 years; no fixed orthodontic appliance; presence of at least 20 teeth; full mouth plaque score (fmps) above 40%. exclusion criteria: subjects with manual disabilities to perform normal oral hygiene maneuvers; subjects allergic to silicone.


Eligibility criteria:
inclusion criteria: * age between 18 and 30 years; * no fixed orthodontic equipment; * presence of at least 20 teeth; * full mouth plaque score (fmps) above 40%. exclusion criteria: * subjects with manual disabilities to perform normal oral hygiene maneuvers; * subjects allergic to silicone
safety study of itacitinib (incb039110) in combination with gemcitabine and nab-paclitaxel in subjects with advanced solid tumors

Conditions: Solid Tumors; Pancreatic Cancer

Summary: test the hypothesis that itacitinib (incb039110) can be administered safely in combination with gemcitabine and nab-paclitaxel in subjects with advanced or metastatic cancer.

study part 1: this is a dose optimization phase designed to find a tolerated regimen that includes identifying the mtd of itacitinib (incb039110) (within a defined pharmacologic range) in combination with doses of gemcitabine and nab-paclitaxel that have established safety and tolerability in subjects with advanced or metastatic solid tumors. study part 2 and part 2a: this phase will explore the safety and tolerability of the mtd or pad of itacitinib (incb039110) when administered in combination with gemcitabine and nab-paclitaxel in subjects with untreated advanced or metastatic pancreatic cancer.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed solid tumor (part 1) or pancreatic adenocarcinoma (part 2) * eastern cooperative oncology group (ecog) performance status ≤ 1 * received no more than 1 prior chemotherapy regimen for advanced or metastatic disease (not including neo-adjuvant and/or adjuvant therapy) (part 1) * received no prior chemotherapy for advanced or metastatic disease (part 2 and part 2a) * adequate renal, hepatic, and bone marrow function without frequent blood product or hematopoietic growth factor support (eg use of erythropoietin or transfusions \> 2 units packed red blood cells every 3 months) * ability to swallow and retain oral medication exclusion criteria: * any known contraindications to the use of a required comedication (gemcitabine or nab-paclitaxel). * evidence of uncontrolled brain metastases or history of uncontrolled seizures. * ongoing radiation therapy and/or radiation therapy administered within 28 days of enrollment or ongoing radiotherapy-related toxicities. * presence of ≥ grade 2 neuropathy. * inability to swallow food or any condition of the upper gi tract that precludes administration of oral medications. * recent (≤ 3 months) history of partial or complete bowel obstruction. * unwillingness to be transfused with blood components. * known history of hepatitis b or c infection or hiv infection
a pilot observational study to assess changes in biochemical parameters of ovarian reserve with chemotherapy

Conditions: Breast Cancer

Summary: premenopausal women who are diagnosed with breast cancer are frequently treated with chemotherapy. chemotherapy can affect the ovaries, and the effects can range from temporary loss of menstrual periods to permanent menopause. it is difficult to predict how an individual's ovarian function will be affected by chemotherapy. there are a number of hormones which can be measured in the blood which are related to fertility and ovarian function. the levels of these hormones may change with chemotherapy, and may relate to the effect of chemotherapy on the ovaries. in this study, we plan to enroll 28 women ranging in age from 25 to 50 who are diagnosed with breast cancer and will be treated with chemotherapy. we will check blood levels of the hormones before, immediately after, and 1 year after treatment with chemotherapy. we will only be checking these blood tests for this study; the type of chemotherapy given will be up to the patient and her oncologist. we will also ask some questions about factors that can influence the levels of these hormones, such as number of children, age of menopause of other family members, and smoking history. the results from this study will be used to help us develop future studies looking at changes in ovarian function with chemotherapy, and the effects of other breast cancer therapies, such as endocrine therapy, on the ovaries.


Eligibility criteria:
inclusion criteria: * subjects must be women with a histologically confirmed invasive adenocarcinoma of the breast (stage i, ii, or iii) with no evidence of metastatic disease. * patients must be planning to receive neoadjuvant or adjuvant chemotherapy. patients may receive concurrent trastuzumab as indicated. if a patient has not yet undergone final surgical resection, it must be highly likely (but is not required to be definite) that the patient will be treated with adjuvant chemotherapy. * patients must have: * reached their 25th birthday and not yet reached their 51st birthday at the time of study enrollment, and * had menses within 3 months prior to starting chemotherapy * patients must not have received prior cytotoxic chemotherapy for any oncologic, rheumatologic, or dermatologic condition. * patients must not have had prior bilateral oophorectomy or pelvic radiation, and must not have had prior hysterectomy * ecog performance status 0 - 2 * pregnant or nursing women may not participate. women of reproductive potential must agree to use an effective non-hormonal contraceptive method, such as condoms, tubal ligation, non-hormonal intrauterine device, partner sterilization, and abstinence during chemotherapy. * all patients must be informed of the investigational nature of this study and given written informed consent in accordance with institutional and federal guidelines.

Keywords: premenopausal women with breast cancer
tdcs in post-acute covid-19 patients with sards

Conditions: Rheumatic Diseases; Autoimmune Diseases

Summary: some patients develop "post-acute covid-19 syndrome," in which they experience persistent symptoms after recovering from the acute phase of covid-19 infection. this syndrome may be more significant in patients with systemic autoimmune rheumatic diseases (sards) who have been suffering from several symptoms associated to sards, such as myalgia, fatigue, and general pains. the transcranial direct current stimulation (tdcs) technique has been frequent, for example, to relieve fatigue and general pains in general population. however, to date, there are no studies evaluating this technique in ard patients with post-acute covid-19; therefore, the main objective of the opened study is to evaluate the safety and efficacy of the application of acute tdcs in ard patients with post-acute covid-19.

currently, there are no studies evaluating the tdcs technique in ard patients with post-acute covid-19; therefore, the main objective of the present study is to evaluate the safety and efficacy of the application of acute tdcs in these specific patients.

Eligibility criteria:
inclusion criteria: * patients with well-defined ards (rheumatoid arthritis, sclerosis systemic, sjögren syndrome, spondyloarthritis, systemic lupus erythematosus, systemic vasculitis, and systemic autoimmune myopathies) * fatigue or general pains. exclusion criteria: * neoplasia, using heart pacemarker, using visceral metalic clips, infections (hiv, htlv-1, hepatitis), pregnance, previous historical of convulsions or epilepsies
role of glucagon in glucose control in cystic fibrosis related diabetes

Conditions: Cystic Fibrosis; Cystic Fibrosis Related Diabetes

Summary: this project is designed to begin to characterize the abnormalities of glucagon secretion in subjects with cystic fibrosis related diabetes along the spectrum of glucose tolerance. cystic fibrosis patients with normal glucose tolerance as well as cystic fibrosis related diabetes as well as control subjects will undergo an oral glucose tolerance test, mixed meal tolerance test, and one step hypoglycemic clamp. cystic fibrosis patients will then return 12 months later to undergo repeat mixed meal tolerance test and hypoglycemic clamp test.

this project is designed to begin to characterize the abnormalities of glucagon secretion in subjects with cystic fibrosis related diabetes along the spectrum of glucose tolerance. this will be a descriptive, cross-sectional and longitudinal cohort study in a sample of children and young adults with cf and a continuum of glucose tolerance compared to healthy age-matched controls. cystic fibrosis patients with normal glucose tolerance as well as cystic fibrosis related diabetes as well as control subjects will be admitted to the research unit on three separate occasions to undergo an oral glucose tolerance test, mixed meal tolerance test, and one step hypoglycemic clamp. cystic fibrosis patients will then return 12 months later to undergo repeat mixed meal tolerance test and hypoglycemic clamp test.

Eligibility criteria:
inclusion criteria: * diagnosis of cf by clinical or genetic determination * normal glucose tolerance or cfrd * subjects routinely taking systemic or inhaled glucocorticoids on stable regimen are eligible exclusion criteria: * subjects with active pulmonary infection requiring supplemental doses of corticosteroids * use of any oral diabetes medications * subjects who are pregnant/lactating * subjects with poor compliance with pancreatic enzyme replacement therapy control subjects: approximately 10 control subjects who are matched for age, gender, are expected to be enrolled in the study. non-cf subjects must be \>12 years old, in good health and not taking any medications or have any medical problems the doctor feels would prevent the subject from completing the study and have bmi between 15-85% for age and gender. control subjects whose fasting blood glucose is found to be \>110 mg/dl will not be continued in the study.
virtual single-energy imaging and de-metallic artifact technology in reducing spinal metallic artifacts

Conditions: Spinal Disease

Summary: 1. compare the effect of virtual single energy imaging and virtual single energy combined with mar technology to remove metal artifacts in the spine. 2. discuss the most suitable kev of virtual single energy imaging combined with mar technology to remove metal artifacts.

the virtual single-energy imaging of energy spectrum ct combined with the metal artifact reduction technology mars multi artifact reduction system\] can effectively reduce the interference of metal artifacts. this is because mar technology corrects the image through an iterative algorithm, improves the spatial resolution, and restores the details of the adjacent tissue of the metal object. virtual single-energy imaging technology can effectively reduce hardening artifacts. the two are used in combination to achieve the purpose of reducing metal artifacts. there have been articles about virtual single energy combined with mar technology to reduce metal artifacts. however, the current researches mostly focus on the comparison of virtual single energy combined with mar technology and conventional ct examination and virtual single energy imaging. there are few evaluations on the severity of metal artifacts after spinal surgery. according to different surgical methods, metal the difference in the number of implants will result in different artifact reduction effects. secondly, the current research on the suitable kev of virtual single energy combined with mar technology to reduce metal artifacts is less discussed and reported.

Eligibility criteria:
inclusion criteria: * patients undergoing surgery due to lumbar disc herniation or prolapse * patients undergoing surgical correction due to vertebral deformities. exclusion criteria: * the scan image quality caused by the patient's movement and other factors is too poor to meet the diagnostic requirements. * patients with only spinous processes and intervertebral spaces undergoing metal fixation after spine surgery * patients after spinal cord tumor surgery.
visual outcome of traumatic posterior segment complications

Conditions: Eye Injuries

Summary: to identify the demographic, the clinical characteristics and the possible predictive factors affecting long-term visual outcomes of traumatic posterior segment complications presenting to assiut university hospital.

ocular trauma is an important public health problem which is preventable and its etiology, severity, and outcome depends on many factors in the changing environment . even eyes represent only 0.27% of the body surface area and 4% of the facial area, they are the third most commonly trauma-exposed area after the hands and feet . it is estimated that, worldwide, there are approximately 1.6 million people blind from eye injuries, 2.3 million bilaterally visually impaired and 19 million with unilateral visual loss; these facts make ocular trauma the most common cause of unilateral blindness . in population-based surveys, the percentage of monocular blindness due to trauma ranged from 20% to 50% and of bilateral blindness from 3.2% to 5.5% . ocular injuries vary with a broad range of severity and include simple subconjunctival injury, lid laceration, corneal abrasion, traumatic iritis, hyphaema, lens injury, vitreous haemorrhage (vh) , retinal detachment, traumatic optic neuropathy, retrobulbar haemorrhage, orbital fracture, and ruptured globes. ocular injuries are classified into 2 groups as open and close globe injuries. ruptured globes fall into the category of open globe injuries, which are injuries resulting in a full-thickness laceration of the cornea and/or sclera. wounds can be penetrating (with one entry wound and no exit wound), or perforating (a through-and-through injury with both entrance and exit wounds) . closed globe injuries resulting from blunt trauma can cause hyphaema, vitreous haemorrhage, retinal tears and detachment, choroidal rupture, macular oedema, and even globe rupture, retrobulbar haemorrhage and traumatic optic neuropathy . in kasr el aini hospital the majority of ocular trauma in their population was due to assaultive injuries occurring mainly in males. open globe injuries were more common than closed globe injuries, and globe lacerations were more common than ruptured globes . in upper egypt pediatric ocular trauma among patients referred to their tertiary ophthalmology referral center over a period of 1 year was 3.7%. of these, 67.3% of cases had open globe injury, 30.7% had closed injury, and only 2% had chemical injury. posterior segment ocular trauma is still an important cause of visual loss and disability in working-age population. with modern surgical approaches, many eyes can be salvaged with retention of vision(9). these complications are retinal detachment (rd), vitreous hemorrhage(vh), posterior intraocular foreign body (iofb), dislo-cated lens, choroidal detachment(10)

Eligibility criteria:
inclusion criteria: all patients presenting with traumatic posterior segment complications in outpatient clinics and operative rooms exclusion criteria: * a history of recent intraocular surgery * no history of trauma. * loss to follow-up
outcome of pulpotomy with mta and biodentin in permanent teeth with caries exposure

Conditions: Pulpitis - Irreversible

Summary: the success of pulpotomy treatment is affected by the type of biologically active material used.the effects of mta and biodentine are compared in mature permanent teeth with caries exposure.it is expected that pulpotomy using biodentine will have a high success rate in caries exposed mature teeth compared to mineral trioxide aggregate.


Eligibility criteria:
inclusion criteria: * mature permanent teeth exclusion criteria: * teeth with restorations